HC Wainwright reiterated their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA - Free Report) in a research note published on Tuesday,Benzinga reports. They currently have a $18.00 price target on the biotechnology company's stock. HC Wainwright also issued estimates for Enanta Pharmaceuticals' Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.81) EPS, Q4 2025 earnings at ($2.00) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($9.50) EPS, FY2027 earnings at ($9.80) EPS, FY2028 earnings at ($9.50) EPS and FY2029 earnings at ($8.15) EPS.
Several other brokerages also recently weighed in on ENTA. JMP Securities reaffirmed a "market outperform" rating and issued a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Robert W. Baird lowered their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating on the stock in a report on Tuesday, November 26th. Two analysts have rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Enanta Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $17.25.
Read Our Latest Research Report on ENTA
Enanta Pharmaceuticals Stock Performance
NASDAQ ENTA traded down $0.39 during trading on Tuesday, reaching $7.11. The company's stock had a trading volume of 317,292 shares, compared to its average volume of 561,088. The firm has a market cap of $151.68 million, a price-to-earnings ratio of -1.30 and a beta of 0.54. Enanta Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $17.80. The business's fifty day moving average price is $5.74 and its 200-day moving average price is $9.50.
Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, beating analysts' consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. As a group, sell-side analysts forecast that Enanta Pharmaceuticals will post -5.05 EPS for the current fiscal year.
Insider Buying and Selling
In related news, CEO Jay R. Luly acquired 45,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 12th. The shares were purchased at an average price of $5.69 per share, with a total value of $256,050.00. Following the completion of the acquisition, the chief executive officer now owns 846,638 shares in the company, valued at approximately $4,817,370.22. This represents a 5.61 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 13.89% of the stock is owned by insiders.
Institutional Trading of Enanta Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in the stock. Oxford Asset Management LLP purchased a new stake in Enanta Pharmaceuticals during the fourth quarter worth about $137,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at about $105,000. Tower Research Capital LLC TRC lifted its holdings in shares of Enanta Pharmaceuticals by 46.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 2,274 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Enanta Pharmaceuticals by 52.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 297,106 shares of the biotechnology company's stock valued at $1,708,000 after purchasing an additional 102,646 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Enanta Pharmaceuticals by 9.3% in the fourth quarter. Marshall Wace LLP now owns 930,087 shares of the biotechnology company's stock valued at $5,348,000 after purchasing an additional 79,197 shares in the last quarter. Hedge funds and other institutional investors own 94.99% of the company's stock.
Enanta Pharmaceuticals Company Profile
(
Get Free Report)
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.
Featured Stories
Before you consider Enanta Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enanta Pharmaceuticals wasn't on the list.
While Enanta Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
